Candesartan + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Congestive Heart Failure

Conditions

Congestive Heart Failure

Trial Timeline

Jun 1, 1999 → May 1, 2003

NCT ID

NCT00634712

About Candesartan + Placebo

Candesartan + Placebo is a phase 3 stage product being developed by AstraZeneca for Congestive Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00634712. Target conditions include Congestive Heart Failure.

What happened to similar drugs?

6 of 20 similar drugs in Congestive Heart Failure were approved

Approved (6) Terminated (5) Active (10)

✅Dapagliflozin + PlaceboAstraZenecaApproved

✅Low Dose Bisoprolol + High Dose BisoprololMerckApproved

✅vildagliptin + placebo of vildagliptinNovartisApproved

✅Angiotensin-Converting Enzyme Inhibitor + Angiotensin II Type 1 Receptor Blocker + sacubitril/valsartanNovartisApproved

✅atorvastatin + placeboPfizerApproved

✅EplerenonePfizerApproved

🔄Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00699452	Phase 3	UNKNOWN	May 1, 2009	Dec 1, 2014	Aortic Valve Stenosis
NCT00319202	Approved	Terminated	Jun 1, 2006	Feb 1, 2012	Glucose Intolerance
NCT00328302	Approved	UNKNOWN	Sep 1, 2000	Apr 1, 2006	Diabetes, Type I
NCT00634712	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634309	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634400	Phase 3	Completed	Mar 1, 1999	May 1, 2003	Congestive Heart Failure

Competing Products

20 competing products in Congestive Heart Failure

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	16
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + Placebo	AstraZeneca	Phase 3	40
AC2592 + placebo	AstraZeneca	Phase 2	35
Dapagliflozin + Placebo	AstraZeneca	Approved	43
Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinate	AstraZeneca	Phase 3	32
Candesartan + Placebo	AstraZeneca	Phase 3	40
Candesartan + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin	AstraZeneca	Phase 3	40
KW-3902IV	Merck	Phase 2	35
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
KW-3902IV	Merck	Phase 2	35
Sitagliptin	Merck	Phase 1	29
Low Dose Bisoprolol + High Dose Bisoprolol	Merck	Approved	43
rolofyline + Comparator Placebo (unspecified)	Merck	Phase 2	35
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
rolofylline + Comparator: Placebo (unspecified)	Merck	Phase 3	40
vildagliptin + placebo of vildagliptin	Novartis	Approved	43
Relaxin + Placebo	Novartis	Phase 2/3	38
Relaxin	Novartis	Phase 2	35